In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. - Rifkin RM; Costello CL; Birhiray RE; Kambhampati S; Richter J; Abonour R; Lee HC; Stokes M; Ren K; Stull DM; Cherepanov D; Bogard K; et al. (Future oncology (London, England), 2024)